Food Allergy Pipeline Insight Report 2023 (Updated) | Companies - Merck & Co, DBV technologies, Genentech, Camallergy, Regeneron Pharmaceuticals, InnoUp Farma, Aravax, Novartis, and Others

DelveInsight's report titled "Food Allergy Pipeline Insight, 2023" offers extensive information on more than 30+ companies and over 35+ pipeline drugs in the field of Food Allergy research. The report encompasses detailed profiles of the Food Allergy pipeline drugs, including information on clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

The research on the Food Allergy pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, clinical trial studies conducted for Food Allergy, any NDA approvals obtained for Food Allergy, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

To explore more information on the latest breakthroughs in the Food Allergy Pipeline treatment landscape of the report, click here @ Food Allergy Pipeline Outlook- https://www.delveinsight.com/report-store/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Food Allergy Pipeline Report
• DelveInsight's Food Allergy pipeline analysis depicts a robust space with 30+ active players working to develop 35+ Food Allergy pipeline treatment therapies.
• The leading Food Allergy companies proactively working to develop potential drug candidates to improve the Food Allergy treatment options include Merck & Co, AstraZeneca, Mabylon, GI Innovation, Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta Therapeutics, IgGenix, Rho Federal Systems Division, Inc, and many others.
• Promising Food Allergy pipeline therapies such as Viaskin Peanut/DBV712, CA002, Omalizumab, Ligelizumab, Dupixent, Viaskin Milk, ADP101, PVX108, INT 301, PRT100, STMC-103H, AR601, and others are under development in different phases of clinical trials.
• In March 2022, Aravax, announced that it had received a green light for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA). PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy.
• In January 2022, Alladapt Immunotherapeutics Inc., announced the completion of patient enrollment in Harmony, its Phase 1/2 study of ADP101 for the treatment of food allergy (FA).DP101, the Company's lead program, is a potentially best-in-class oral immunotherapy (OIT) designed to desensitize patients allergic to one or multiple foods simultaneously to mitigate the risk of severe, life-threatening allergic reactions.

Food Allergy Overview
A food allergy occurs when the body's immune system sees a certain food as harmful and reacts by causing symptoms. This is an allergic reaction. Foods that cause allergic reactions are allergens. The results of skin prick tests (SPT), IgE total and specific antibodies, and patient histories are not predictive of true food allergy, as they are not able to establish the causal and temporal relationship between the intake of the suspect food and the hypersensitivity reaction.

For further information, refer to the detailed Food Allergy Unmet Needs, Food Allergy Market Drivers, and Food Allergy Market Barriers, click here for Food Allergy Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Food Allergy Emerging Drugs Profile
• Viaskin Peanut: DBV technologies
• Omalizumab: Genentech
• Dupilumab: Regeneron Pharmaceuticals
• ADP101: Alladapt Immunotherapeutics

Food Allergy Pipeline Therapeutics Assessment
There are approx. 30+ Food Allergy companies which are developing the Food Allergy therapies. The companies which have their Food Allergies drug candidates in the most advanced stage, i.e. preregistration include, DBV technologies.

Request a sample and discover the recent advances in Food Allergy Ongoing Clinical Trial Analysis and Medications, click here @ Food Allergy Treatment Landscape- https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Food Allergy Pipeline Therapeutics Assessment
• Food Allergy Assessment by Product Type
• Food Allergy by Stage and Product Type
• Food Allergy Assessment by Route of Administration
• Food Allergy by Stage and Route of Administration
• Food Allergy Assessment by Molecule Type
• Food Allergy by Stage and Molecule Type

Some of the Companies in the Food Allergy Therapeutics Market include-
Merck & Co, AstraZeneca, Mabylon, GI Innovation, Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta Therapeutics, IgGenix, Rho Federal Systems Division, Inc, and many others.

Dive deep into rich insights for drugs for Food Allergy Pipeline, click here @ Food Allergy Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Food Allergy Pipeline Report
• Coverage- Global
• Food Allergy Companies- Merck & Co, AstraZeneca, Mabylon, GI Innovation, Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta Therapeutics, IgGenix, Rho Federal Systems Division, Inc, and others.
• Food Allergy Pipeline Therapies- Viaskin Peanut/DBV712, CA002, Omalizumab, Ligelizumab, Dupixent, Viaskin Milk, ADP101, PVX108, INT 301, PRT100, STMC-103H, AR601, and others.
• Food Allergy Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Got Queries? Find out the related information on Food Allergy Mergers and acquisitions, Food Allergy Licensing Activities @ Food Allergy Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Food Allergy Executive Summary
3. Food Allergies: Overview
4. Food Allergy Pipeline Therapeutics
5. Food Allergy Therapeutic Assessment
6. Food Allergies - DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Viaskin Peanut: DBV technologies
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Dupilumab: Regeneron
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ADP101: Alladapt Immunotherapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Research programme : antiallergy therapeutics: IgGenix
18. Food Allergy Drug profiles in the detailed report…..
19. Inactive Products
20. Food Allergies Key Companies
21. Food Allergies Key Products
22. Food Allergies- Unmet Needs
23. Food Allergies- Market Drivers and Barriers
24. Food Allergies- Future Perspectives and Conclusion
25. Food Allergies Analyst Views
26. Food Allergies Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

This release was published on openPR.